Remoxipride hydrochloride

Research use only, not for human use.

Dopamine D2 receptor antagonist.

Dopamine D2 receptor antagonist.(In Vivo):In male Sprague-Dawley rats, Remoxipride hydrochloride (0.1-100 μM/kg; i.p.) blockes apomorphine-induced hyperactivity and dose-dependent blockades apomorphine-induced behaviors. In beagle dogs, Remoxipride hydrochloride (0.25-5 μM/kg; gavage) blockes apomorphine-induced vomiting.

(S)-Remoxipride hydrochloride (1-100 μM; 20 min) shows binding efficiency with IC50s of ＞100, 1.57 and 42 μM for dopamine D1, dopamine D2 and α1-Adrenoccptor, respectively.

(S)-Remoxipride hydrochloride (0.1-100 μM/kg; i.p. 60 min prior to apomorphine) blockades apomorphine-induced behaviors s in rats and vomiting in dogs.(S)-Remoxipride hydrochloride (0.1-10 mg/kg; i.p. 30 min prior to apomorphine) displaces [3H]spiperone from both striatal and extra-striatal areas.

Roxiam | (S)-Remoxipride Hydrochloride | Remoxipride Hydrochloride Anhydrous

Others

Other Targets

——

——

——

73220-03-8

407.73

C16H24BrClN2O3

>98% (HPLC)

——

Cl.CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC

——

(-20℃)

With Ice Pack

≥ 2 years